Two multinational pharmaceutical companies, France's Sanofi and UK's GSK, on Thursday announced the start of the Phase 1/2 clinical trial for their jointly developed COVID-19 vaccine, APA reports citing Sputnik.
"Following encouraging pre-clinical study results, today Sanofi and GSK announce the start of the Phase 1/2 clinical trial for our COVID19 vaccine," Sanofi said on Twitter.